Serbian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

glaucoma/главобоља

Веза се чува у привремену меморију
Страна 1 од 23 резултати

Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
FIELD OF THE INVENTION The invention provides cyclohexylamine derivatives as N-Methyl-D-Aspartate (NMDA) antagonists, pharmacological compositions comprising the derivatives, and methods of treating diseases and disorders responsive to antagonism of NMDA receptors using the derivatives. BACKGROUND

4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs, as well as novel intermediates of the 4-substituted analogs. The analogs are selectively active as antagonists of

4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs, as well as novel intermediates of the 4-substituted analogs. The analogs are selectively active as antagonists of

2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is related to 2-substituted piperidine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also directed to the use of 2-substituted piperidine analogs as

2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is related to 2-substituted piperidine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also directed to the use of 2-substituted piperidine analogs as

4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also

Piperidine derivatives as subtype selective N-Methyl-D-Aspartate antagonists

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
FIELD OF INVENTION The invention relates to piperidine derivatives as N-Methyl-D-Aspartate (NMDA) antagonists useful in the treatment of diseases and disorders responsive to antagonism of NMDA receptors. BACKGROUND OF THE INVENTION Many of the physiological and pathophysiological effects of the

Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
CROSS REFERENCE TO RELATED APPLICATIONS This application is a 371 of International Application No. PCT/EP2010/057598 filed Jun. 1, 2010. The invention relates to 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-- 2-ylamino)phenyl]-benzamide (also known as "imatinib"

Process of using anti-inflammatory furanones as selective calcium channel inhibitors

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND Manoalide is a compound isolated from a marine sponge [E. D. de Silva et al., Tetrahedron Letters 21:1611-1614 (1980)] which has anti-inflammatory, immunosuppressive and analgesic properties. Manoalide the structure of which is shown below, includes a 5-hydroxy-2(5H)-furanone moiety,

Compositions and methods for the treatment of moderate to severe pain

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1840/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050924 filed on 4 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this

Amines that inhibit a mammalian anandamide transporter, and methods of use thereof

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

Amines that inhibit a mammalian anandamide transporter, and methods of use thereof

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

Amines that inhibit a mammalian anandamide transporter, and methods of use thereof

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

Cyclic triazo and diazo sodium channel blockers

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
The present invention relates to triazine compounds and cyclic diazo analogs thereof having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. U.S. Pat. No. 4,649,139 discloses compounds of the formula

Cyclic triazo and diazo sodium channel blockers

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
CROSS-REFERENCE TO RELATED APPLICATIONS This application is the National Stage of International Application No. PCT/GB2009/050033, filed on Jan. 16, 2009, which claims the priority date of United Kingdom Application No. 0800741.1, filed on Jan. 16, 2008 the contents of both being hereby incorporated
Придружите се нашој
facebook страници

Најкомплетнија база лековитог биља подржана науком

  • Ради на 55 језика
  • Биљни лекови потпомогнути науком
  • Препознавање биљака по слици
  • Интерактивна ГПС мапа - означите биље на локацији (ускоро)
  • Читајте научне публикације повезане са вашом претрагом
  • Претражите лековито биље по њиховим ефектима
  • Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима

Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима

Google Play badgeApp Store badge